Sierra Oncology
1820 Gateway Drive
Suite 110
San Mateo
California
94404
United States
Tel: 650-376-8679
Website: https://sierraoncology.com/
About Sierra Oncology
194 articles about Sierra Oncology
-
Sierra Oncology Signs Exclusive Global In-Licensing Agreement with AstraZeneca for Novel BET Inhibitor to Expand Myelofibrosis Pipeline
8/5/2021
Sierra Oncology, Inc. (NASDAQ: SRRA), a late-stage biopharmaceutical company on a mission to deliver targeted therapies that treat rare forms of cancer, today announced it has acquired an exclusive global license from AstraZeneca (LSE/STO/NASDAQ: AZN) for AZD5153, a potent and selective BRD4 BET inhibitor with a novel bivalent binding mode.
-
Sierra Oncology Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
8/5/2021
Sierra Oncology, Inc. granted stock options to three new employees as approved by the Compensation Committee of the Company’s Board of Directors, under Sierra Oncology’s 2018 Equity Inducement Plan.
-
Sierra Oncology Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) - July 22, 2021
7/22/2021
Sierra Oncology, Inc., a late-stage biopharmaceutical company on a mission to deliver targeted therapies that treat rare forms of cancer, granted a stock option to a new employee as approved by the Compensation Committee of the Company’s Board of Directors, under Sierra Oncology’s 2018 Equity Inducement Plan.
-
Sierra Oncology Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - July 07, 2021
7/7/2021
Sierra Oncology, Inc., a late-stage biopharmaceutical company on a quest to deliver targeted therapies that treat rare forms of cancer, granted stock options to five new employees as approved by the Compensation Committee of the Company’s Board of Directors, under Sierra Oncology’s 2018 Equity Inducement Plan.
-
Sierra Oncology Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) - June 23, 2021
6/23/2021
Sierra Oncology, Inc., a late-stage biopharmaceutical company on a quest to deliver targeted therapies that treat rare forms of cancer, granted a stock option to a new employee as approved by the Compensation Committee of the Company's Board of Directors, under Sierra Oncology's 2018 Equity Inducement Plan.
-
Sierra Oncology Announces Completion of Enrollment for MOMENTUM Phase 3 Trial
6/21/2021
Sierra Oncology, Inc., a late-stage biopharmaceutical company on a quest to deliver targeted therapies that treat rare forms of cancer, announced the completion of enrollment for its pivotal Phase 3 MOMENTUM clinical trial evaluating the novel JAK1, JAK2 and ACVR1 / ALK2 inhibitor momelotinib in myelofibrosis patients who are symptomatic and anemic.
-
Sierra Oncology Hosting KOL Panel Event to Discuss Momelotinib Data Presented at EHA 2021
6/14/2021
Sierra Oncology, Inc. today announced it will host an an analyst and investor event on Monday, June 21 at 4:30 pm ET.
-
Momelotinib Oral Presentation at European Hematology Association Demonstrates Association Between Transfusion Independence and Improved Overall Survival
6/11/2021
Sierra Oncology, Inc. announced data presented at the European Hematology Association Annual Meeting highlighting transfusion independence with momelotinib is associated with improved overall survival, including in patients with anemia at baseline.
-
Sierra Oncology Welcomes Two New Independent Directors to its Board
6/3/2021
Sierra Oncology, Inc. (SRRA), a late-stage biopharmaceutical company on a quest to deliver targeted therapies that treat rare forms of cancer, today announced Georgia Erbez and Christy Oliger have joined the Company's Board of Directors.
-
Sierra Oncology Announces Presentation at Jefferies Healthcare Conference - May 25, 2021
5/25/2021
Sierra Oncology, Inc., a late-stage biopharmaceutical company on a quest to deliver targeted therapies that treat rare forms of cancer, announced that the company will participate in the 2021 Jefferies Healthcare Conference being held virtually from June 1-4, 2021.
-
Sierra Oncology Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) - May 21, 2021
5/21/2021
Sierra Oncology, Inc., a late-stage biopharmaceutical company on a quest to deliver targeted therapies that treat rare forms of cancer, granted a stock option to a new employee as approved by the Compensation Committee of the Company's Board of Directors, under Sierra Oncology's 2018 Equity Inducement Plan.
-
Sierra Oncology Announces Abstracts Accepted for American Society of Clinical Oncology Annual Meeting
5/19/2021
New momelotinib analysis examining the association between transfusion independence and overall survival to be presented
-
Sierra Oncology Announces Oral Presentation at European Hematology Association Annual Meeting
5/12/2021
– Oral presentation for new momelotinib analysis examines association between transfusion independence and overall survival – – Poster presentation to highlight improved transfusion independence of momelotinib irrespective of baseline degree of anemia, platelet count or transfusion status –
-
Sierra Oncology Reports First Quarter 2021 Results
5/7/2021
Sierra Oncology, Inc. (SRRA), a late-stage biopharmaceutical company on a quest to deliver targeted therapies that treat rare forms of cancer, today reported its financial and operating results for the first quarter ended March 31, 2021.
-
Sierra Oncology Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) - Mar 23, 2021
3/23/2021
SAN MATEO, Calif., March 23, 2021 /PRNewswire/ - Sierra Oncology, Inc., a late-stage biopharmaceutical company on a quest to deliver targeted therapies that treat rare forms of cancer, granted a stock option to a new employee as approved by the Compensation Committee of the Company's Board of Directors, under Sierra Oncology's 2018 Equity Inducement Plan.
-
Sierra Oncology Reports 2020 Year End Results
3/11/2021
MOMENTUM Phase 3 Trial on Track to Complete Enrollment in mid-2021 with Top-line Data Anticipated in H1 2022 – – Data Presented Throughout the Year Included Long-Term Overall Survival, Efficacy in Various Patient Subsets and Dosing Durability – – Key Appointments Made to Executive Team in Preparation for Commercial Execution
-
Sierra Oncology to Present at Three Upcoming Investor Conferences
3/3/2021
—HC Wainwright Life Sciences Conference beginning at 7:00 am ET on March 9th— —Roth Conference at 10:00 am ET on March 15 th — —Oppenheimer Healthcare Conference at 1:50 pm ET on March 17 th —
-
Sierra Oncology Announces Presentation at LifeSci Partners Precision Oncology Day
2/12/2021
Sierra Oncology, Inc. (SRRA), a late-stage biopharmaceutical company on a quest to deliver targeted therapies that treat rare forms of cancer, today announced that President and Chief Executive Officer Stephen Dilly , MBBS, PhD, will present an overview of the company at the LifeSci Partners Precision Oncology Day
-
Sierra Oncology Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) - Feb 09, 2021
2/9/2021
Sierra Oncology, Inc., a late-stage biopharmaceutical company on a quest to deliver targeted therapies that treat rare forms of cancer, granted a stock option to a new employee as approved by the Compensation Committee of the Company's Board of Directors, under Sierra Oncology's 2018 Equity Inducement Plan.
-
Sierra Oncology to Present at H.C. Wainwright 2021 BioConnect Virtual Conference
1/5/2021
Sierra Oncology, Inc. announced that President and Chief Executive Officer Stephen Dilly, MBBS, PhD, will present an overview of the company at the H.C. Wainwright 2021 BioConnect Virtual Conference taking place January 11-14, 2021.